Clinical Trials Logo
  1. Home
  2. Chronic Kidney Disease (CKD)
  3. NCT04042350

Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis

Chronic Kidney Disease (CKD) Clinical Trial

Official title:
A Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis Treatment Using Data From the AURORA Study

Clinical Trial Summary

The purpose of this study is to evaluate which clinical and laboratory factors are associated with major adverse cardiovascular event (MACE) in chronic kidney disease (CKD) patients on dialysis. The study will also establish a cardiovascular (CV) risk equation appropriate for this dialysis population.

Clinical Trial Description

This study is a retrospective analysis of dialysis dependent CKD patients participating in AURORA. The retrospective analysis will be performed using the AURORA study database. AURORA was a prospective clinical trial in which dialysis patients were randomly assigned to rosuvastatin or placebo, sponsored by AstraZeneca. Patients included in the AURORA study who had end stage renal disease (ESRD) and had been treated with regular hemodialysis or hemofiltration for at least 3 months. Patients were recruited from approximately 300 centers in 25 countries. The clinical study data is held by AstraZeneca AB, Sweden. No formal sample size calculation was performed. The sample size is based on the available data from the AURORA study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04042350
Study type Observational
Source Astellas Pharma Inc
Contact
Status Completed
Phase
Start date May 22, 2019
Completion date February 19, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT05422755 - The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Recruiting NCT04064827 - A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) Phase 3
Completed NCT02218099 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease Phase 1/Phase 2
Completed NCT02276742 - Lifestyle Management of CKD in Obese Diabetic Patients N/A
Completed NCT01222234 - Impact of Vitamin D Therapies on Chronic Kidney Disease N/A
Recruiting NCT05106387 - An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
Completed NCT05373303 - The Clinical Study for Evaluating The Safety And Efficacy Of Epodion® N/A
Completed NCT01247311 - Vitamin D and the Health of Blood Vessels in Kidney Disease N/A
Completed NCT02733328 - Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Enrolling by invitation NCT06322641 - A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
Completed NCT05755373 - A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
Completed NCT02678000 - Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function Phase 2
Completed NCT02185911 - Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis N/A
Terminated NCT03226899 - A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment Phase 4
Completed NCT02504294 - A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis Phase 3
Active, not recruiting NCT04094831 - Community-based Screening of Chronic Kidney Disease (CKD) and Measure the Impact of Health Education N/A
Completed NCT01810939 - A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Phase 3
Enrolling by invitation NCT06447038 - Pilot Study for the Early Detection of Chronic Kidney Disease, Non-Dialysis Objective (NDO).